Search Results 2311-2320 of 18881 for Relapse
A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma. Scottsdale ...
... relapse of Crohn's disease after surgical resection. AMG 181 in Subjects with Moderate to Severe Crohn's Disease Rochester, MN. This is a randomized, double ...
... relapse of Crohn's disease after surgical resection. Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year Rochester, MN. The purpose of this ...
Understanding complete remission, partial remission and relapse of proteinuria in FSGS. Products & services. A Book: Mayo Clinic Family Health Book · Newsletter ...
Root Cause of Multiple Myeloma Relapse Revealed. Dana Sparks. September 18, 2013. Mayo Clinic Receives $8.8 Million Federal Grant for Metabolomics Center.
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...
The exact prevalence of imperforate anus in the newborn population is unknown. Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory ...
Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia. Rochester, Minn. This phase II ...
Primary Goal: To determine the toxicity of in-house, manufactured MUC1-activated T cells in patients with relapsed/refractory MUC1-expressing multiple myeloma.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!